MetaCap

Atara Biotherapeutics (ATRA) vs OKYO Pharma (OKYO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OKYO Pharma (OKYO) has outperformed Atara Biotherapeutics (ATRA) over the past year, losing 49.5% versus a loss of 53.7%. Atara Biotherapeutics is the larger company by market cap ($64.5 million vs $56.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATRA-53.73%OKYO-49.53%
+53%-11%-75%
Nov 21, 20251 yearNov 20, 2026
ATRA-95.09%OKYO-64.33%
+73%-16%-105%
May 16, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATRA versus OKYO key metrics
MetricATRAOKYO
Share price$6.33$1.07
Market cap$64.49M$56.15M
1-day change-0.16%-7.76%
YTD return-65.01%-48.31%
1-year return-53.73%-49.53%
5-year return-98.56%—
Forward P/E3.96—
EPS (TTM)$-1.12$-0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$120.77M—
Revenue growth (YoY)-6.33%—
Net income (latest FY)$32.69M$-4.71M
Operating margin29.69%—
Net margin27.07%—
52-week high$19.15$3.20
52-week low$3.92$1.00
Distance from 52-week high-66.94%-66.56%
Analyst consensusbuystrong_buy
Avg. price target upside+115.96%+678.50%
Average volume35.46K143.41K
Shares outstanding10.19M52.48M
Employees105
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Atara Biotherapeutics

ATRA stock →

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees

About OKYO Pharma

OKYO stock →

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees

ATRA vs OKYO FAQ

Which is bigger, Atara Biotherapeutics or OKYO Pharma?

Atara Biotherapeutics (ATRA) is larger, with a market capitalization of $64.49M compared with $56.15M for OKYO Pharma (OKYO).

Which stock has performed better over the past year, ATRA or OKYO?

OKYO returned -49.53% over the past 12 months, compared with -53.73% for ATRA (price return, excluding dividends). Past performance does not predict future results.

Are Atara Biotherapeutics and OKYO Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons